Table 1.
Biological functions and roles of circular RNAs in cancer diagnostics and therapeutics.
| circRNA | Associated Cancer (s) | Regulation (Up ↑, Down↓) | Biological Function | Target (s) | Type of model | Type of cell line (s) | Biomarker/therapeutics | References |
|---|---|---|---|---|---|---|---|---|
| circ_0009910 | AML | ↑ | Sponges miR-20a-5p and inhibits apoptosis. Overexpressing miR-20a-5p counteracts chemoresistance in vitro and in vivo through targeting KIF26B by modulating the activities of the MAPK/ERK and cAMP/PKA signaling pathways | miR-20a-5p | Human, Mouse; in vitro/in vivo | Human cell lines – Mono-Mac-6, KG-1, AML2, AML5 | +/− | Ping et al., 2019a |
| GC | ↑ | Associated with distant metastasis and differentiation; downregulation reduces GC cell proliferation, migration and invasion. Acts as oncogene that acts by inducing the EMT. Its knockdown suppresses the migration invasion and EMT of GC cells in vitro. | – | Human; in vitro | Human cell lines – BGC823, SGC7901, AGS, MGC803, MKN45, GES1 | +/+ | Liu M. et al., 2018 | |
| CML | ↑ | Promotes cell growth and imatinib resistance, reduces apoptosis and autophagic activation. It accelerates imatinib-resistance in cells by modulating ULK1-induced autophagy via targeting miR-34a-5p, providing a potential target in imatinib resistance of CML. | miR-34a-5p | Human; in vitro | Human cell lines – K562, K562/R | +/+ | Cao et al., 2020 | |
| OSC | ↑ | Sponges miR-449a which targets IL6R; prohibits cell-cycle arrest, promotes proliferation and inhibits apoptosis. | miR-449a | Human; in vitro | Human cell lines – MG63, Saos-2, U2OS, hFOB | +/+ | Deng et al., 2018 | |
| circ-vimentin | AML | ↑ | Associated with poor overall survival (OS), leukemia-free survival and vimentin expression. | – | Human; in vivo | – | +/− | Yi and Lin, 2018 |
| circ_0075001 | AML | ↑ | Lowers expression of components of Toll-like receptor signaling pathway | – | Human; in vitro | Human cell lines – NB-4, KASUMI-1, OCI-AML5, OCI-AML3, ME-1, MV4-11, K562 | +/− | Hirsch et al., 2017 |
| circ_0004277 | AML | ↓ | – | – | Human; in vivo | – | +/− | Li W. et al., 2017 |
| circ_100053 | CML | ↑ | Associated with clinical stage, BCR/ABL mutant status and imatinib resistance | – | Human; in vivo | – | +/− | Ping et al., 2019b |
| circ–RPL15 | CLL | ↑ | Inhibits miR-146b-3p mediated suppression of the RAS/RAF1/MEK/ERK pathway | miR-146b-3p | Human; in vitro | Human cell lines – MEC-1 and JVM-3 | +/+ | Wu Z. et al., 2019 |
| circ-CBFB | CLL | ↑ | Activates Wnt/β-catenin signaling pathway | miR-607 | Human; in vitro | Human cell line - MEC-1 | +/+ | Xia L. et al., 2018 |
| circ_0007841 | MM | ↑ | Correlated with chromosomal aberrations such as gain 1q21, t (4:14), mutations in ATR and IRF4 genes; miR-199a-3p affects the multi-chemoresistance of OS via targeting AK4; overexpression correlates with osteolytic bone destruction in MM; overexpressed in BTZ-resistant MM cell lines | miR-199a-3p | Human; in vitro | Human cell lines – THP-1, KM3, U266, RPMI-8226, KM3/BTZ, 146 U266/BTZ, RPMI-8226/BTZ | +/− | Gao et al., 2019 |
| circ_0000190 | MM | ↓ | Correlates with prognosis survival rates of MM patients, inhibits MM progression via modulating miR-767-5p/MAPK4 pathway | miR-767-5p | Human, Mouse; in vitro/in vivo | Human cell lines – MM.1S, NCI-H929 | +/+ | Feng et al., 2019 |
| GC | ↓ | Associated with tumor diameter, lymphatic metastasis, distal metastasis, TNM stage and CA19-9 level | – | Human; in vivo | – | +/– | Chen et al., 2017 | |
| OSC | ↓ | Correlated with bigger tumor size, advanced staging (IIB/III) and distant metastasis | miR-767-5p | Human, Mouse; in vitro/in vivo | Human cell lines –hFOB1.19, SAOS-2, MG63, U2OS, SJSA1, and HOS | +/– | Li et al., 2020 | |
| circ-SMARCA5 | MM | ↓ | Higher expression is correlated with lower β2-MG level and less advanced ISS stage; native resistance to drugs is common due to multiple chromosomal abnormities in the pathogenesis of MM | miR-767-5p | Human; in vitro | Human cell lines – NCI-H929, RPMI8226, U226, OPM2, JJN3 | +/+ | Liu H. et al., 2019 |
| GC | ↓ | Correlates with differentiation, lymph node metastasis, vascular invasion | – | Human; in vitro | Human cell lines – GES-1, MGC803, MKN45, AGS, MKN74, BGC-823, SGC-7901 | +/– | Cai et al., 2019 | |
| HCC | ↓ | Promotes apoptosis and expression of tumor suppressor TIMP3, inhibits proliferation, invasion and metastasis; reverses tumor growth along with decreased expression of MMP9 and MMP7 | miR-17-3p miR-181b-5p | Human; in vitro | Human cell lines – Huh7, HCCLM9, HepG2 | +/+ | Li Z. et al., 2019 | |
| circRNA_101237 | MM | ↑ | Increases significantly in bortezomib-resistant cell lines; overexpression is associated with a poor response to chemotherapy in MM patients | – | Human; in vitro | Human cell lines – THP-1, MM.1S, H929, MM.1S/BTZ, H929/BTZ | +/– | Liu and Wang, 2020 |
| HCC | ↑ | Associated with tumor size, lymph node metastasis, distant metastasis and TNM stage; cisplatin resistance associated with loss of Runt- associated transcription factor 3 and upregulation of cyclophilin B | – | Human; in vitro | Human cell lines – HCCLM3, Hep3B, MHCC97-H, cisplatin-resistant Huh7/DDP cells | +/– | Zhou et al., 2020 | |
| circ-APC | BCL | ↓(DLBCL) | Inhibits Wnt/β-catenin signaling | miR-888 | Human, Mouse; in vitro/in vivo | Human cell lines – SUDHL-3, U2932, TMD8, OCI-Ly3, L428, GM12878 | +/+ | Hu et al., 2019 |
| CDR1as | CRC | ↑ | Enhances EGFR/RAF1/MAPK pathway, induces cell growth, resistance to apoptosis and cell cycle arrest | miR-7 | Human; in vitro | Human cell lines –HCT-116, DLD-1, NCM460, CCD841CoN | +/+ | Weng et al., 2017 |
| HCC | ↑ | Promotes HCC progression by activating PI3K/AKT/mTOR pathway | miR-7 | Human; in vivo | – | +/+ | Xu et al., 2017 | |
| GC | ↑ | Activates PTEN/PI3K/AKT pathway | miR-7 | Human, Mouse; in vitro/in vivo | Human cell lines – MGC-803, HGC-27, GES-1 | +/+ | Pan et al., 2018 | |
| circCCDC66 | CRC | ↑ | Promote CRC growth and metastasis by stabilizing MYC mRNA | miRNA-33b, miR-93 | Human; in vitro/in vivo | Human cell lines – HCT-116, HT-29 | +/– | Hsiao et al., 2017 |
| circ_0004585 | CRC | ↑ | Associated with increased patient's tumor size | – | Human; in vivo | – | +/– | Tian et al., 2019 |
| circ_0007142 | CRC | ↑ | Regulates proliferation and invasion of CRC; upregulation is associated with lymphatic metastasis | miR-103a-2-5p | Human; in vitro | Human cell lines – HCT-116, HT-29, LoVo, HCO | +/– | Zhu et al., 2019 |
| circHUEW1 | CRC | ↑ | Associated with lympho-vascular invasion, lymph node metastasis, distant metastasis, and TNM stage; affects IGF2/β-catenin signaling pathway | miR-486 | Human; in vivo, in vitro | Human cell lines – HCT116, SW480 | +/+ | Chen H. Y. et al., 2020 |
| circ_0001178 | CRC | ↑ | Metastatic clinical features, advanced TNM stage and adverse prognosis; induces EMT through increasing ZEB1 expression | miR-382, miR-587 and miR-616 | Human, Mouse; in vitro/in vivo | Human cell lines – NCM460 cells, CRC LoVo, SW620 | +/+ | Ren et al., 2020 |
| circ_0005075 | CRC | ↑ | Downregulation modulated Wnt/β-catenin pathways and reduced cell proliferation and metastasis; Knockdown suppresses EMT progression by decreasing the levels of Vimentin and N-cadherin | – | Human; in vivo, in vitro | Human cell lines – HCO, SW480, SW620, HT29, HCT116, SW1116, LOVO | +/+ | Jin et al., 2019 |
| HCC | ↑ | Contributes to HCC proliferation, invasion, and metastasis | miR-23b-5p, miR-93-3p, miR581,miR-23a-5p | Human; in vivo | – | +/– | Shang et al., 2016 | |
| circHIPK3 | CRC | ↑ | Promotes CRC progression,increases expression of downstream oncogenic target genes, FAK, IGF1R, EGFR, and YY1 that activate PI3K/AKT and MEK/ERK signaling pathways to promote cancer progression and drug resistance | miR-7 | Human, Mouse; in vitro/in vivo | Human cell lines – FHC, HCT116, HT29, SW480, SW620, DLD1 | +/+ | Zeng et al., 2018 |
| OSC | ↓ | Correlates with Enneking stage and lung metastasis. | – | Human; in vitro | Human cell lines – SaoS2, HOS, KH-OS, MG63, 143B, U2OS | +/– | Kun-peng et al., 2018b | |
| BCa | ↓ | Reduces aggressiveness and metastasis by targeting the miR-558/heparanase axis | miR-558 | Human, Mouse; in vitro/in vivo | Human cell lines –T24T, UMUC3, SV-HUC-1, HUVEC, | +/+ | Li Y. et al., 2017 | |
| circ_0001649 | CRC | ↓ | – | – | Human; in vitro | Human cell line - H116 | +/– | Ji et al., 2018 |
| HCC | ↓ | Associated with tumor size, occurrence of tumor embolus; correlates with metastasis, | – | Human; in vitro | Human cell lines – HCC–LM3, MHCC-97L | +/– | Qin et al., 2016 | |
| LC | ↓(NSCLC) | associated with shorter OS, positive lymph node, and differentiation grade | miR-331-3p miR-338-5p | Human, Mouse; in vitro/in vivo | Human cell lines – A549, H358, H1299, H1581, 16HBE | +/– | Liu H. et al., 2018 | |
| circITGA7 | CRC | ↓(CRC) | Inactivates Ras signaling pathway; associated with tumor size, lymph metastasis, distant metastasis, and TNM stage | miR-370-3p | Human, Mouse; in vitro/in vivo | Human cell lines – SW480, RKO, Caco-2, SW620, LoVo, HCT116, DLD1, FHC | +/– | Li X. et al., 2018a |
| circ_0000711 | CRC | ↓ | – | – | Human; in vitro | Human cell lines – NCM460, HCT116, COLO205, HT29 | +/– | Li J. et al., 2018b |
| circ_0014717 | CRC | ↓ | Overexpression promotes G0/G1 phase arrest, reduces growth, invasion and distal metastasis | – | Human, Mouse; in vitro/in vivo | Human cell lines – HCT116, HT29, SW480, FHC | +/– | Wang F. et al., 2018 |
| circFBXW7 | BC | ↓(TNBC) | Inhibits tumor progression; up-regulates FBXW7 and degrades c-Myc, negatively correlated with metastasis | miR-197-3p | Human, Mouse; in vitro/in vivo | Human cell lines – MCF-10A, MCF-7, T47D, BT474, SKBR-3, MDA-MB-453, MDA-MB-468, MDAMB-231, BT549, HCC38, 4T1, MA-891 | +/+ | Ye F. et al., 2019 |
| circSEPT9 | BC | ↑(TNBC) | Activates LIF/Stat3 signaling pathway, correlates with lymph node metastasis | miR-637 | Human, Mouse; in vitro/in vivo | Human cell lines – MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-453, SUM-159, MCF-10A | +/– | Zheng et al., 2020 |
| circ_0001785 | BC | ↑(BC) | Associated with histological grade, TNM stage and distant metastasis | – | Human; in vivo | – | +/– | Yin et al., 2018 |
| circCDYL | BC | ↑ | Regulates miR-1275-ATG7/ULK1 axis; downregulates the expression of autophagy associated genes AKT and ULK1; enhances malignant progression | miR-1275 | Human, Mouse; in vitro/in vivo | Human cell lines – MDA-MB231, MCF-7 | +/+ | Liang et al., 2020 |
| MM | ↑ | Promotes MM growth by targeting YAP; inhibits apoptosis | miR-1180 | Human, Mouse; in vitro/in vivo | Human cell lines – MM1.S, NCI-H929 | +/+ | Chen F. et al., 2020 | |
| circKIF4A | BC | ↑(TNBC) | Induces TNBC cell proliferation and migration regulating the expression of KIF4A; miR-375 can sensitize resistant cells to tamoxifen and partly reverse EMT | miR-375 | Human, Mouse; in vitro/in vivo | Human cell lines – MCF10A, MCF-7, T47D, BT474, KBR3, MDA-MB-453, MDA-MB-468, MDA-MB-231, BT549, HCC38 | +/– | Tang et al., 2019 |
| circPLK1 | BC | ↑(TNBC) | Promotes TNBC cell proliferation and metastasis by regulating PLK1 | miR-296-5p | Human, Mouse; in vitro/in vivo | Human cell lines – MCF10A, MDAMB-468, MDA-MB-453, MDA-MB-231, HCC38, BT549 | +/– | Kong Y. et al., 2019 |
| circHMCU | BC | ↑(BC) | Enhanced proliferation and metastasis; can modify EMT pathway, promotes mesenchymal phenotypes and inhibits epithelial phenotypes; stable and resistant to ActD treatment | let-7 family | Human, Mouse; in vitro/in vivo | Human cell lines –MDA-MB-231, MDA-MB-468, MCF7 | +/– | Song et al., 2020 |
| circ_0068033 | BC | ↓(BC) | Overexpression induces apoptosis | miR-659 | Human, Mouse; in vitro/in vivo | Human cell lines – MCF10A, MCF-7, T47D, MDA-MB-468 | +/– | Yuan et al., 2020 |
| circ_0005075 | HCC | ↑ | Contributes proliferation, invasion, and metastasis | miR-23b-5p, miR-93-3p, miR581 and miR-23a-5p | Human; in vivo | – | +/– | Shang et al., 2016 |
| circ_100338 | HCC | ↑ | Increased cell metastasis progression; regulates the MTOR signaling pathway | miR-141-3p | Human; in vitro | Human cell lines –Hep3B, BEL7402, MHCC97H, HCCLM6 | +/+ | Huang X. Y. et al., 2017 |
| circRHOT1 | HCC | ↑ | Promotes HCC progression, recruits TIP60,enhances invasion, inhibits apoptosis, and promotes metastasis | – | Human, Mouse; in vitro/in vivo | Human cell lines –Hep3B, Huh7 | +/+ | Wang L. et al., 2019 |
| circ_0091579 | HCC | ↑ | Associated with poor OS | – | Human; in vivo | +/– | Zhang C. et al., 2018 | |
| circ-HOMER1 | HCC | ↑ | Increases the expression of CXCL6; associated with larger tumor size, higher TNM stage, and worse prognosis | miR-1322 | Human; in vitro | Human cell lines – Sk-Hep-1, SMMC-7721, HCCLM3, Huh-7, HepG2 cells, L02 | +/– | Zhao M. et al., 2020 |
| circ_0016788 | HCC | ↑ | Downregulates miR-486/CDK4 expression; associated with poor OS | miR-486 | Human; in vivo | - | +/+ | Cheng et al., 2020 |
| circ_0078602 | HCC | ↓ | Associated with a poor prognosis | - | Human; in vivo | – | +/– | Kou et al., 2019 |
| circC3P1 | HCC | ↓ | Associated with TNM stage, tumor size and vascular invasion, overexpression decreased metastatic nodules | miR-4641 | Human, Mouse; in vitro/in vivo | Human cell lines –BEL7402, Hep3B, HuH7, MHCC97-L, HL-7702 | +/- | Zhong et al., 2018 |
| circ-ITCH | HCC | ↓ | Correlated with poor OS | - | Human; in vivo | – | +/– | Guo et al., 2017 |
| BCa | ↓ | Inhibits cell proliferation, migration and invasion through circ-ITCH/miR-17,miR-224/p21,PTEN signaling axis | miR-17,miR-224 | Human, Mouse; in vitro/in vivo | Human cell lines – EJ, T24, 253 J, RT4, TCC-SUP, UMUC, J82, 5637, SV-HUC | +/+ | Yang C. et al., 2018 | |
| CRC | ↓ | Overexpression reduces cell proliferation by downregulating c-Myc and cyclinD1 | miR-7, miR-20a | Human; in vitro | Human cell lines – HCT116, SW480 | +/+ | Huang et al., 2015 | |
| circMTO1 | HCC | ↓ | Promotes expression of a tumor suppressor p21 resulting in reduced tumor cell proliferation, metastasis and invasion | miR-9 | Human, Mouse; in vitro/in vivo | Human cell lines – HepG2, SMMC-7721, QGY-7701, SK-Hep1 | +/+ | Han et al., 2017 |
| circ_0013520 | GBM | ↑ | Correlated with tumor size, TNM and worse OS | – | Human; in vitro | Human cell lines – SHG-44, U251, HEB | +/– | Zhou and Fan, 2020 |
| circ_0004379 | GBM | ↑ | Correlated with tumor size, TNM and worse OS | – | Human; in vitro | Human cell lines – SHG-44, U251, HEB | +/– | Zhou and Fan, 2020 |
| circ-CDC45 | GBM | ↑ | Associated with larger tumor size, higher grade, and worse survival | miR-516b, miR-527 | Human; in vitro | Human cell lines – U87MG, U118, U251, LN229 | +/- | Liu J. et al., 2019 |
| circNFIX | GBM | ↑ | Predicts poor prognosis; promotes cell propagation and migration; knockdown enhances TMZ sensitivity in resistant cells; regulates NOTCH pathway | miR-132, miR-34a-5p | Human, Mouse; in vitro/in vivo | Human cell lines – HA1800, SF-539, SHG-44, U87 | +/+ | Xu et al., 2018; Ding et al., 2020 |
| circ_0013958 | LC | ↑(LAC) | Associated with the TNM stage and lymphatic metastasis | miR-134 | Human; in vitro | Human cell lines – A549, H1299, BEAS-2B | +/– | Zhu X. et al., 2017 |
| circFARSA | LC | ↑(NSCLC) | Promotes cell migration and invasion; upregulates FASN | miR-330-5p, miR-326 | Human; in vitro/in vivo | Human cell line – A549 | +/– | Hang et al., 2018 |
| CRC | ↑ | Promotes proliferation, migration, and invasion;regulates miR-330-5p/LASP1 axis | miR-330-5p | Human, Mouse; in vitro/in vivo | Human cell lines – FHC, LS174T, RKO, HT29, HCT116, SW480 | +/+ | Lu C. et al., 2020 | |
| circ_0014130 | LC | ↑(NSCLC) | Associated with tumor volume, distant metastasis;upregulates Bcl2 | miR-136-5p | Human, Mouse; in vitro/in vivo | Human cell lines – PC-9, A549 | +/– | Geng Y. et al., 2020 |
| circ_0000792 | LC | ↑(LAD) | Overexpression is correlated with T stage, distant metastasis | – | Human; in vivo | – | +/– | Li, 2018 |
| circ_100876 | LC | ↑(NSCLC) | Related to carcinogenesis of NSCLC and it might serve as a potential prognostic biomarker and therapeutic target | – | Human; in vivo | – | +/+ | Yao J. T. et al., 2017 |
| circFADS2 | LC | ↑ | Associated with advanced TNM stage, lymph node metastasis, poor differentiation, and shorter OS; induces progression, invasion and proliferation | miR-498 | Human; in vitro | Human cell line – HepG2 | +/+ | Zhao F. et al., 2018 |
| CRC | ↑ | Associated with distant metastasis | - | Human; in vivo | – | +/– | Xiao et al., 2020 | |
| circPVT1 | LC | ↑(NSCLC) | Associated with distant metastasis; promotes cell proliferation, migration and invasion, and inhibits apoptosis through upregulated E2F2 and E2F2-related protein expression | miR-125b | Human, Mouse; in vitro/in vivo | Human cell lines – A549, H292, SPC-A1, H1299, H1650, H1975, SK-MES-1, HBE | +/+ | Li X. et al., 2018c |
| OSC | ↑ | Associated to chemoresistance and lung metastasis; knockdown decreases ABCB1 expression, promotes chemoresistance; knockdown partly reverses the doxorubicin and cisplatin resistance | – | Human; in vitro | Human cell lines – SaoS2, KHOS, U2OS, MG63 | +/+ | Kun-peng et al., 2018b | |
| ALL | ↑ | Promotes cell proliferation and inhibits apoptosis | let-7,miR-125 | Human; in vivo, in vitro | Human ALL cell lines | +/+ | Hu et al., 2018 | |
| circ_0067934 | LC | ↑(NSCLC) | Tumor-promoting circRNA; induces cell proliferation, metastasis and invasion | – | Human; in vitro | Human cell lines – A549, H1299, SK-MES-1, PC-9, BEAS-2B | +/- | Wang and Li, 2018 |
| ESCC | ↑ | Promotes proliferation and migration | – | Human; in vitro | Human cell lines – TE-13, ECA-109 | +/+ | Zong et al., 2018b | |
| LSCC | ↑ | Promote cell proliferation and metastasis | miR-1324 | Human; in vitro | Human cell lines – TU212, TU686, 16HBE | +/– | Chu, 2020 | |
| HCC | ↑ | Enhances migration, invasion and proliferation of cells; regulates Wnt/β-catenin signaling pathway | miR-1324 | Human; in vitro | Human cell lines – BEL7402, Hep3B, HuH7, MHCC97-L, HL-7702 | +/+ | Zhu et al., 2018 | |
| circPRKCI | LC | ↑ | Upregulation increased proliferation and tumorigenesis | miR-545, miR-589 | Human, Mouse; in vitro/in vivo | Human cell lines – A549, NCI-H1975, NCI-H1703, NCI-H226, NCI-H46, PC9, NCI-H1299, SPC-A1, HCC827, HBE | +/– | Qiu et al., 2018 |
| circ_0000064 | LC | ↑ | Promotes cell proliferation and inhibits cell apoptosis, enhances expression of bcl-2; overexpression is correlated with TNM stage, lymph node metastasis, | – | Human; in vitro | Human cell lines – A549, H1229 | +/+ | Luo et al., 2017 |
| circ_0016760 | LC | ↑(NSCLC) | miR-1287 directly targets GAGE1, higher expression associated with shorter OS, correlated with lymph node metastasis | miR-1287 | Human, Mouse; in vitro/in vivo | Human cell lines – A549, H358, H1299, H1975 | +/– | Li Y. et al., 2018 |
| circ_102231 | LC | ↑(LAC) | Promotes lung cancer cells proliferation, migration and invasion | – | Cell line model (in vitro exp) | Human cell lines – BEAS-2B, A549 | +/+ | Zong et al., 2018a |
| circRNA_103809 | LC | ↑ | Regulates miR-4302/ZNF121/MYC loop; promotes tumor growth, cell proliferation and invasion, associated with tumor stage and lymph node metastasis | miR-4302 | Human, Mouse; in vitro/in vivo | Human cell lines – A549, H125, 95D, NCI-H292, H1975, HBE | +/+ | Liu W. et al., 2018 |
| CRC | ↓ | Promote apoptosis through FOXO4 activity | miR-532-3p | Human; in vitro | Human cell lines – SW620, HCT116, COCA-2, HT29, FHC | +/+ | Bian et al., 2018 | |
| circ_0005962 | LC | ↑(LAC) | – | – | Human; in vivo | – | +/– | Liu X. X. et al., 2019 |
| circ_0086414 | LC | ↓(LAC) | Associated with EGFR mutations | – | Human; in vivo | – | +/– | Liu X. X. et al., 2019 |
| circ-PRMT5 | LC | ↑(NSCLC) | Correlated with larger tumor, LNM, poor OS and progression free survival; upregulates EZH2 | – | Human, Mouse; in vitro/in vivo | Human cell lines – HBE, A549, 95-D, HCC827, H1299, SK-MES-1 | +/– | Wang Y. et al., 2019 |
| GC | ↑ | Promotes GC cell growth, clone formation, migration and invasion and inhibits apoptosis | miR-145, miR-1304 | Human; in vitro | Human cell lines – AGS, MKN-28, MKN45, BGC823, MGC803, SGC7901, GES-1 | +/+ | Du et al., 2019 | |
| circ-RAD23B | LC | ↑(NSCLC) | Regulates miR-593e3p/CCND2 axis; increases cell invasion via miR-653e5p/TIAM1 pathway | miR-593e3p, miR-653e5p | Human; in vitro | Human cell lines – 16HBE, H1299, H1581, H358, A549 | +/+ | Han et al., 2019 |
| circ_0102533 | LC | ↑(NSCLC) | Associated with tumor type, TNM stages, lymph nodes metastasis and distant metastasis or recurrence | – | Human; in vitro | Human cell lines – A549, H1299, H1792, SK-MES-1, SPC-A1 | +/– | Zhou X. et al., 2018 |
| circ_0079530 | LC | ↑ | Enhances cell proliferation and invasion | – | Human; in vitro | Human cell lines – A549, H1299, H460, Calu1, BEAS-2B | +/– | Li J. et al., 2018a |
| circFGFR3 | LC | ↑(NSCLC) | Increases cell invasion and proliferation, regulates Gal-1, pAKT, and p-ERK1/2 | miR-22-3p | Human; in vitro | Human cell lines – 95C, 95D, A549, H460 | +/– | Qiu B. Q. et al., 2019 |
| circ_000984 | LC | ↑(NSCLC) | Promotes cell proliferation and metastasis; regulates Wnt/β-catenin signaling | – | Human; in vitro | Human cell lines – H1975, SPC-A1, H1299, HCC827, PC 9, A549, BEAS-2B | +/– | Li X. et al., 2019 |
| circ_0001946 | LC | ↑(LAC) | Regulates SIRT1 that activates Wnt/β-catenin signaling pathway | miR-135a-5p | Human, Mouse; in vitro/in vivo | Human cell lines – H1299, A549, Calu3, SPC-A1, BEAS-2B | +/– | Yao et al., 2019 |
| GBM | ↓ | Reduces the migration, invasion, and proliferation of GBM cells | miR-671-5p | Human, Mouse; in vitro/in vivo | Human cell lines – U87, U251, HM | +/+ | Li, 2019a | |
| circ_0037515 | LC | ↓(NSCLC) | – | – | Human; in vivo | – | +/– | Zhao D. et al., 2020 |
| circ_0037516 | LC | ↓(NSCLC) | – | – | Human; in vivo | – | +/- | Zhao D. et al., 2020 |
| circ_0033155 | LC | ↓(NSCLC) | Reduces cell proliferation, colony formation and migration, correlated with lymphatic metastasis | – | Human; in vitro | Human cell lines – HCC827, H1975 | +/+ | Gu et al., 2018 |
| circ_100395 | LC | ↓ | Promotes LC malignancy regulating miR-1228/TCF21 axis | miR-1228 | Human; in vitro | Human cell lines – A549, H460, Beas-2B | +/+ | Chen D. et al., 2018 |
| circ-FOXO3 | LC | ↓(NSCLC) | Promotes NSCLC development; releases FOXO3; miR-155 and FOXO transcription factors affect chemoresistance | miR-155 | Human; in vitro | Human cell lines – A549, SPC-A1, NCI-H1299, NCI-H1650, SK-MES-1 | +/+ | Zhang Y. et al., 2018 |
| circ_0056616 | LC | ↑(LAD) | Upregulation is correlated with TNM stage and lymph node metastasis | – | Human; in vitro | Human cell lines – PC9, PC14, HEK293T | +/– | He Y. et al., 2020 |
| circ_0010882 | GC | ↑ | Contributes to the proliferation of GC cells, migration, invasion, and apoptosis through modulating PI3K/Akt/mTOR pathway | – | Human; in vitro | Human cell lines – HGC-27, MKN-45, SGC-7901, BGC-823, GES-1 | +/– | Peng et al., 2020 |
| circ-DCAF6 | GC | ↑ | Enhances GC progression | miR-1231, miR-1256 | Human; in vitro | Human cell lines – AGS, BGC823, MGC803, GES1 | +/– | Wu L. et al., 2019 |
| circ_0000419 | GC | ↓ | Associated with tumor stage, lymphatic and distal metastasis, venous and perineural invasion | hsa-miR-141-5p, hsa-miR-589-3p | Human; in vitro | Human cell lines – BGC-823, HGC-27, MGC-803, SGC-7901, GES-1 | +/– | Tao et al., 2020 |
| circ_0006156 | GC | ↓ | Associated with lymph node metastasis, nerve invasion and degree of tumor differentiation | – | Human; in vivo | – | +/– | He F. et al., 2020 |
| circ_0001821 | GC | ↓ | Negatively associated with tumor depth and lymph node metastasis | – | Human; in vitro | Human cell lines – SGC-7901, HGC-27, BGC-823, AGS, MKN-1 | +/- | Kong S. et al., 2019 |
| circCCDC9 | GC | ↓ | Upregulation sponges miR-6792-3p that targets CAV1, a tumor suppressor gene | miR-6792-3p | Human, Mouse; in vitro/in vivo | Human cell lines – GES-1, AGS, BGC-823, HGC-27, MGC-803, MKN-28, MKN-45, SGC-7901 | +/+ | Luo Z. et al., 2020 |
| circRHOBTB3 | GC | ↓ | Prevents the growth of cells, promotes expression of p21 | miR-654-3p | Human, Mouse; in vitro/in vivo | Human cell lines – AGS, HGC27, MKN45 | +/+ | Deng et al., 2020 |
| circ_100269 | GC | ↓ | Resists GC development | miR-630 | Human; in vitro | Human cell lines – AGS, MKN28, MKN45, BGC823, MGC803, SGC7901, GES1 | +/+ | Zhang Y. et al., 2017 |
| circ_0000745 | GC | ↓ | Associated with tumor differentiation | – | Human; in vivo | – | +/– | Huang M. et al., 2017 |
| circPSMC3 | GC | ↓ | Contributes to GC progression by regulating PTEN/miRNA-296-5p axis; PTEN regulates chemoresistance | miRNA-296-5p | Human, Mouse; in vitro/in vivo | Human cell lines – BGC823, MGC803, SGC7901, AGS, MKN45 | +/- | Rong et al., 2019 |
| circ-KIAA1244 | GC | ↓ | Associated with TNM stage, lymphatic metastasis | – | Human; in vivo | – | +/– | Tang et al., 2018 |
| circYAP1 | GC | ↓ | Decreases GC cell growth and invasion; regulates miR-367-5p/p27 Kip1 axis | miR-367-5p | Human, Mouse; in vitro/in vivo | Human cell lines – GES-1, HGC-27 | +/– | Liu H. et al., 2018 |
| circ_0006848 | GC | ↓ | Correlates with tumor differentiation and tumor size | – | – | – | +/– | Lu et al., 2019a |
| circ_0000520 | GC | ↓ | Associated with TNM stage | – | Human; in vitro | Human cell lines – MKN-45, BGC-823, MGC- 80 803, AGS | +/– | Sun et al., 2017 |
| circ_0001895 | GC | ↓ | Associated with cell differentiation, Borrmann type, and tissue CEA expression | – | Human; in vitro | Human cell lines – GES-1, AGS, BGC-823, HGC27, MGC-803, SGC-7901 | +/– | Shao et al., 2017 |
| circ_0005556 | GC | ↓ | Downregulation correlated with differentiation, TNM stage and lymphatic metastasis | – | Human; in vivo | – | +/– | Yang L. et al., 2019 |
| circ_0067582 | GC | ↓ | – | – | Human; in vivo | – | +/– | Yu et al., 2020 |
| circ_0000467 | GC | ↑ | Promotes proliferation, migration, and invasion of GC cells,inhibits tumor apoptosis | – | Human; in vitro | Human cell lines – HGC-27, MGC-803, AGS, NUGC-3, GES-1 | +/– | Lu et al., 2019b |
| circ_102958 | GC | ↑ | Overexpression is correlated with TNM stage | – | Human; in vivo | – | +/– | Wei et al., 2019 |
| circFUT8 | BCa | ↓ | Inhibits migration and invasion of Bca cells through silencing KLF10-mediated Slug signaling, inhibitory effect on lymphatic metastasis | miR-570-3p | Human, Mouse; in vitro/in vivo | Human cell lines – SV-HUC-1, T24, UM-UC-3 | +/– | He Y. et al., 2020 |
| circ_0071662 | BCa | ↓ | Inhibits cell proliferation and invasion; upregulates HPGD and NF2 | miR-146b-3p | Human; in vivo | – | +/+ | Abulizi et al., 2019 |
| circ_0018289 | CC | ↑ | Associated with poor disease free survival | – | Human; in vivo | – | +/– | He Q. et al., 2020 |
| circ_0001038 | CC | ↑ | Promotes cell metastasis; suppresses inhibition of oncogenic targets like CNNM3 and MACC1 | miR-337-3p | Human; in vivo | – | +/– | Wang Y. et al., 2020 |
| circEIF4G2 | CC | ↑ | Induce cell growth and migration | miR-218 | Human; in vitro | Human cell lines – HeLa, CasKi, C33A, SiHa cells | +/– | Mao et al., 2019 |
| circCLK3 | CC | ↑ | Promotes cell proliferation, EMT, migration and invasion | miR-320a | Human, Mouse; in vitro/in vivo | Human cell lines – SiHa, HeLa, CaSki, C-33A, MS751 | +/– | Hong et al., 2019 |
| circ_0000388 | CC | ↑ | Induces proliferation, migration, invasion,inhibit apoptosis; regulates miR-377-3p/TCF12 axis | miR-377-3p | Human; in vitro | Human cell lines – HeLa, SiHa | +/– | Meng et al., 2020 |
| circ_0101996 | CC | ↑ | – | – | Human; in vivo | – | +/– | Wang Y-M. et al., 2017 |
| circ_0101119 | CC | ↑ | – | – | Human; in vivo | – | +/– | Wang Y-M. et al., 2017 |
| circ_0104649 | CC | ↑ | – | – | Human; in vivo | – | – | Wang Y-M. et al., 2017 |
| circ_0104443 | CC | ↑ | – | – | Human; in vivo | – | – | Wang Y-M. et al., 2017 |
| circFoxO3a | CC | ↓ | Correlates with stromal invasion, positive lymph node metastasis and poor prognosis | – | Human; in vivo | – | +/– | Tang et al., 2020 |
| circ_0081001 | OSC | ↑ | Overexpression was associated with poor prognosis | – | Human; in vitro | Human cell lines – MG63,KHOS,U2OS | +/– | Kun-peng et al., 2018a |
| circ_0002052 | OSC | ↓ | Overexpression suppresses OS cell proliferation, migration and invasion while promoting apoptosis; regulates circ_0002052/miR-1205/APC2/Wnt/b-catenin pathway | miR-1205 | Human; in vitro | Human cell lines – hFOB 1.19, 293T | +/+ | Wu Z. et al., 2018 |
| circ-SLC7A5 | ESCC | ↑ | Overexpression correlated with TNM stage and poor OS | – | Human; in vitro | Human cell lines – K30, K70, K140, K180, K150, K450, T10, T12w | +/– | Wang Q. et al., 2020 |
| circ_0004771 | ESCC | ↑ | Increases the expression of CDC25 | miR-339-5p | Human; in vitro | Human cell lines – FHC, HCT-116, SW480 | +/– | Huang E. et al., 2020 |
| CRC | ↑ | – | – | Human; in vitro | Human cell lines – FHC, HCT-116, SW480 | +/– | Pan et al., 2019 | |
| circ_0092125 | OSCC | ↓ | Correlated with tumor size, TNM stage, and lymph node metastasis | - | Human; in vitro | Human cell lines – SCC15, SCC25, CAL27 | +/– | Gao et al., 2020 |
| circ_0001874 | OSCC | ↑ | Associated with TNM stage and tumor grade | – | Human; in vivo | – | +/– | Zhao S. Y. et al., 2018 |
| circ_0001971 | OSCC | ↑ | Upregulation is associated with TNM stage | – | Human; in vivo | – | +/– | Zhao S. Y. et al., 2018 |
| circ-CCND1 | LSCC | ↑ | Improve the stability of CCND1 mRNA; increases LSCC growth | HuR; miR-646 | Human, Mouse; in vitro/in vivo | Human cell lines –AMC-HN-8, Hep-2, LSC-1, TU212, TU177, TU686, SCC10A, NP-69 | +/– | Zang et al., 2020 |
| circFLNA | LSCC | ↑ | Induces migration of LSCC cells by targeting miR486-3p/FLNA axis; high level of FLNA implicates poor survival and drug resistance | miR486-3p | Human; in vitro | Human cell lines –Tu212, SCC-2, SCC40 | +/+ | Wang J. X. et al., 2019 |
| circMATR3 | HSCC | ↑ | Upregulation of oncogene USP28 that contributes to MYC stability | miR-188-5p, miR-448 | Human; in vitro | Human cell line - FaDu | +/– | Wang Z. et al., 2020 |
| circMORC3 | HSCC | ↓ | Associated with T stages and tumor sizes | – | – | – | +/– | Zheng and Chen, 2020 |
| circMYBL2 | AML | ↑ | Increases the translational efficiency of FLT3 kinase; knockdown impairs the cytoactivity of FLT3-ITD AML cells, including quizartinib-resistant cells | – | Human, Mouse; in vitro/in vivo | Human cell lines – MV4-11, MOLM-13,THP-1, HL60, NB4 and ML-2,U937 | +/+ | Sun et al., 2019 |
| Circ-DLEU2 | AML | ↑ | Induces cell proliferation and reduces apoptosis | miR-496 | Human, Mouse; in vitro/in vivo | Human cell lines – MOLM-13, HL-60, MV-4-11 | +/+ | Wu D. M. et al., 2018 |
| f-circPR | AML | ↑ | Promoted cell proliferation | – | – | – | +/+ | Guarnerio et al., 2016 |
| f-circM9 | AML | ↑ | Favors leukemia progression | – | – | – | +/+ | Guarnerio et al., 2016 |
| circ_001569 | CRC | ↑ | Promotes cell proliferation and invasion | miR-145 | Human; in vitro | Human cell lines – SW480, HCT116, SW620, LOVO | +/+ | Xie et al., 2016 |
| circ_0007534 | CRC | ↑ | Increase in the Bcl2/Bax ratio in CRC cells and inhibits apoptosis | – | Human; in vitro | Human cell lines – SW620, HCT116, LoVo, SW480, HT29 | +/+ | Zhang R. et al., 2018 |
| circ_0000069 | CRC | ↑ | Knockdown induces G0/G1 arrest and inhibits cancer progression | – | Human; in vitro | Human cell lines – HT29, LoVo, HCT-116, SW480 | +/+ | Guo et al., 2016 |
| circ_0020397 | CRC | ↑ | Upregulates TERT and thereby induces cell proliferation | miR-138 | Human; in vitro | Human cell lines – LoVo, HCT116, SW480, SW620 | +/+ | Zhang X. et al., 2017 |
| circBANP | CRC | ↑ | Promotes CRC cell proliferation; induces p-Akt protein expression | – | Human; in vitro | Human cell lines – HT29, HCT116 | +/+ | Zhu M. et al., 2017 |
| circ5615 | CRC | ↑ | promotes CRC progression through miR-149-5p/TNKS axis | miR-149-5p | Human, Mouse; in vitro/in vivo | Human cell lines – HCT 116, LoVo, HT-29, SW480, NCM460 | +/+ | Ma et al., 2020 |
| circPTK2 | CRC | ↑ | Promotes EMT of CRC cells via expression of mesenchymal marker vimentin | – | Human, Mouse; in vitro/in vivo | Human cell lines – HCT15, SW620, SW480, LOVO | +/+ | Yang H. et al., 2020 |
| LC | ↓(NSCLC) | Overexpression augments T1F1γ expression, reduces TGF β induced EMT | miR-429/miR-200b3p | Human, Mouse; in vitro/in vivo | Human cell lines – BEAS-2B, A549, H1299, H1650, SPC-A1, Calu3,H226, H520, SK-MES-1 | +/+ | Wang L. et al., 2018 | |
| circ_0060745 | CRC | ↑ | Promotes CSE1L-mediated CRC cell proliferation and metastasis | miR-4736 | Human; in vitro | Human cell lines – NCM460, HT29, LOVO, PKO, SW480 | +/+ | Wang and Wang, 2020 |
| circ_0008285 | CRC | ↓ | Inhibits CRC cell proliferation and migration; regulates PI3K/AKT pathway | miR-382-5p | Human; in vitro | Human cell lines – SW480, RKO, HCT8, SW620, HCT116, DLD1,FHC | +/+ | Wang et al., 2020 |
| circ-0001313 | CRC | ↑ | Inhibits apoptosis regulating PI3K/Akt signaling pathway | miRNA-510-5p | Human; in vitro | Human cell lines – SW620, HCT116, SW480, HT-29, LoVo, NCM460 | +/+ | Tu et al., 2020 |
| circDDX17 | CRC | ↓ | inhibits cell proliferation, migration, invasion, and promotes apoptosis | hsa-miR-21-5p | Human; in vitro | Human cell lines – SW480, SW620, HT29, LoVo, HCT116, RKO | +/+ | Li X-N et al., 2018 |
| circ-ABCB10 | BC | ↑ | Knockdown suppresses proliferation and induces apoptosis | miR-1271 | Human; in vitro | Human cell lines – MCF-7, MDA- MB-231, MDA-MB-468, MDA-MB-453 | +/+ | Liang et al., 2017 |
| circEHMT1 | BC | ↓ | Inhibits metastasis by regulating circEHMT1/miR-1233-3p/KLF4 axis | miR-1233-3p | Human, Mouse; in vitro/in vivo | Human cell lines – ZR-75-1, MCF-7, MB-468, T47D, SK-BR3, MDA-MB-231, BT-549, HMEpC | +/+ | Lu M. et al., 2020 |
| circ_0011946 | BC | ↑ | Promotes migration and invasion | miR26a/b | Human; in vitro | Human cell lines – HS-578T, T47D, MCF-7, BT549, MDA-MB-231, SKBR-3 | +/+ | Zhou J. et al., 2018 |
| circGFRA1 | BC | ↑(TNBC) | Promotes cell proliferation and inhibits apoptosis; regulates GFRA1 expression | miR-34a | Human, Mouse; in vitro/in vivo | Human cell lines – MCF10A, SKBR3, T47D, BT474, MCF-7, BT-483, BT-20, BT549, MDA-MB-468, MDA-MB-231 | +/+ | He et al., 2017 |
| circ_0001982 | BC | ↑ | Promotes tumorigenesis | miR-143 | Human; in vitro | Human cell lines – MDA-MB-231, MCF-7, MDAMB-468, MDA-MB-435s | +/+ | Tang et al., 2017 |
| circTADA2A | BC | ↓ | Possesses tumor-suppressor capability, restores the expression of SOCS3, suppressed cell proliferation, migration, invasion, clonogenicity | miR-203a-3p | Human, Mouse; in vitro/in vivo | Human cell lines – MCF-7 MDA-MB-231 | +/+ | Xu et al., 2019 |
| circ-10720 | HCC | ↑ | Promotes migration, invasion and EMT by stabilizing vimentin | miR-1246, miR-578, miR-490-5p | Human, Mouse; in vitro/in vivo | Human cell lines – PLC-PRF-5, SMMC-7721, HEK-293T | +/+ | Meng et al., 2018 |
| circPTGR1 | HCC | ↑ | Knockdown promotes expression of epithelial markers and reduces the levels of mesenchymal markers | miR-449a | Human, Mouse; in vitro/in vivo | Human cell lines – HepG2, L-O2, SMCC7721, HEP3B, HUH7, MHCC97-L, MHCC 97H, HCC-LM3 | +/+ | Wang G. et al., 2019 |
| circTRIM33–12 | HCC | ↓ | Upregulates TET1 expression; suppresses tumor proliferation, migration, invasion | miR-191 | Human, Mouse; in vitro/in vivo | Human cell lines – MHCC97-L, HCC97-H, HCCLM3, SMMC-7721 | +/+ | Zhang P. F. et al., 2019 |
| circ-BIRC6 | HCC | ↑ | Knockdown reduces Bcl2 mRNA and protein levels | miR3918 | Human, Mouse; in vitro/in vivo | Human cell lines – SKHEP-1, Huh-7 MHCC97H | +/+ | Tang et al., 2015 |
| circ_0070269 | HCC | ↓ | Increases expression of NPTX1,that inhibits aggressive tumor behavior | miR182 | Human, Mouse; in vitro/in vivo | Human cell lines – Hep3B, SMMC-7721, HepG2, PLC, Huh-7,LO2 | +/+ | Zhang P. F. et al., 2019 |
| circADAMTS13 | HCC | ↓ | Acts as a tumor suppressant; inhibits HCC proliferation | miR-484 | Human; in vitro | Human cell lines – PLC/PRF/5, SK-Hep-1, Hep3B, HepG2 | +/+ | Qiu L. et al., 2019 |
| cZNF292 | GBM | ↑ | Promotes angiogenesis; regulates STAT3/5/β-catenin pathway | – | Human; in vitro | Human cell lines – U87MG and U251 | +/+ | Yang P. et al., 2019 |
| circ_0037251 | GBM | ↑ | Enhances GBM progression, upregulates mTOR; inhibits cell apoptosis and G1 phase arrest | miR-1229-3p | Human, Mouse; in vitro/in vivo | Human cell lines – U373, U251, HEK293T | +/+ | Cao et al., 2019 |
| circMAPK4 | GBM | ↑ | Suppress apoptosis through decreased phosphorylation of p38/MAPK | miR-125a-3p | Human, Mouse; in vitro/in vivo | Human cell lines – U138, U373, U87 | +/+ | He et al., 2020a |
| circ-U2AF1 | GBM | ↑ | Enhances cell proliferation, migration, and invasion, increases expression of NOVA2 | miR-7-5p | Human, Mouse; in vitro/in vivo | Human cell lines – U87MG, U251, U87, HEB | +/+ | Li, 2019a |
| circNT5E | GBM | ↑ | Upregulates NT5E, SOX4, PI3KCA; promotes cell proliferation, migration, and invasion | miR-422a | Human, Mouse; in vitro/in vivo | Human cell lines – U87, U251 | +/+ | Wang R. et al., 2018a |
| circ_0029426 | GBM | ↑ | Promotes cell proliferation, migration and invasion, and inhibits cell apoptosis | miR-197 | Human; in vitro | Human cell lines – U87, U251, LN229, U87MG, A172, NHA | +/+ | Zhang G. et al., 2019 |
| circ-TTBK2 | GBM | ↑ | Regulates circ-TTBK2/miR-217/HNF1β/Derlin-1 axis; promotes cell proliferation, migration, and invasion, while inhibiting apoptosis | miR-217 | Human, Mouse; in vitro/in vivo | Human cell lines – U87, U251, HEK293T | +/+ | Zheng et al., 2017 |
| circMMP9 | GBM | ↑ | Upregulates the expression of (CDK4) and aurora kinase A; promotes proliferation, migration and invasion abilities | miR-124 | Human, Mouse; in vitro/in vivo | – | +/+ | Wang R. et al., 2018b |
| circ_0020123 | LC | ↑(NSCLC) | Upregulates ZEB1 and EZH2 for tumor growth and EMT | miR-144 | Human, Mouse; in vitro/in vivo | Human cell lines – PC9, H1573, A549, SK-MES-1, H1299, Calu-3 | +/+ | Qu et al., 2018 |
| f-circEA-4a | LC | ↑(NSCLC) | Induces cell proliferation, metastasis and invasion | – | Human; in vitro | Human cell lines –A549, HT1299 | +/+ | Tan et al., 2018 |
| f-circEA-2a | LC | ↑(NSCLC) | Promotes cell migration and invasion | – | Human; in vitro | Human cell lines –A549, HT1299 | +/+ | Tan et al., 2018 |
| circ_104916 | GC | ↓ | Inhibits cell proliferation, migration and EMT | – | Human, Mouse; in vitro/in vivo | Human cell lines – AGS, MKN-28, NCI-N87, MKN-45,GES1 | +/+ | Li J. et al., 2017 |
| circPDSS1 | GC | ↑ | Enhances expression of NEK2 leading to cell migration and proliferation | miR-186-5p | Human; in vitro | Human cell lines – MGC-803, HGC-27, BGC-823, GES-1 | +/+ | Ouyang et al., 2019 |
| circ_0023642 | GC | ↑ | Promotes cell proliferation and metastasis; upregulates N-cadherin, Vimentin and Snail expression | – | Human; in vitro | Human cell lines – MGC-803, MNK-45,SGC-7901, HGC-27, GES1 | +/+ | Zhou L. H. et al., 2018 |
| circATAD1 | GC | ↑ | Increases cell progression, upregulates YY1 | miR-140-3p | Human; in vivo, in vitro | Human cell lines – GES1, SGC7901, BGC-823, AGS, MGS-803 | +/+ | Zhang L. et al., 2020 |
| circFN1 | GC | ↑ | Promotes viability and inhibits apoptosis; facilitates CDDP resistance in vitro | miR-182-5p | Human, Mouse; in vitro/in vivo | Human cell lines – SGC7901CDDP, BGC823C DDP, SGC7901, SGC823) | +/+ | Huang X. X. et al., 2020 |
| circCACTIN | GC | ↑ | Induces EMT and regulates Smad signaling, promote metastatic conversion, angiogenesis | miR-331-3p | Human, Mouse; in vitro/in vivo | Human cell lines – GES1, BGC-823, MGC-803, SGC-7901c | +/+ | Zhang L. et al., 2019 |
| circ-CEP85L | GC | ↓ | Inhibits tumor growth, proliferation and invasion of GC cells | miR-942-5p | Human, Mouse; in vitro/in vivo | Human cell lines – MGC-803, AGS, KATOIII, BGC-823, HGC-27, MKN-45 | +/+ | Lu J. et al., 2020 |
| circMYLK | BCa | ↑ | Augments proliferation, migration, the tube formation of HUVEC, and EMT; stabilizes VEGFA | miR-29a | Human, Mouse; in vitro/in vivo | Human cell lines – EJ, T24, 5673, BIU-87 | +/+ | Zhong et al., 2017 |
| circACVR2A | BCa | ↓ | Upregulates EYA4 expression; suppresses proliferation, migration and invasion and metastasis through miR-626/EYA4 axis | miR-626 | Human, Mouse; in vitro/in vivo | Human cell lines – T24, UM-UC-3, RT4, J82, 5637, HT-1376, TCCSUP, SV-HUC-1 | +/+ | Dong et al., 2019 |
| circ_0061140 | Ovarian cancer | ↑ | Regulates miR370/FOXM1 pathway; promotes cell proliferation, migration, and the EMT | miR-370 | Human, Mouse; in vitro/in vivo | Human cell lines – SKOV3, A2780, OV2008, IGROV1, ES-2 | +/+ | Chen Q. et al., 2018 |
| circUBAP2 | OSC | ↑ | Stable expression of Bcl-2; promotes OS growth and inhibits apoptosis | miR-143 | Human, Mouse; in vitro/in vivo | Human cell lines – hFOB 1.19, MG63, U2OS | +/+ | Zhang H. et al., 2017 |
| circ_001564 | OSC | ↑ | Inhibits cell cycle arrest in G0/G1 phase and apoptosis | miR-29c-3p | Human; in vitro | Human cell lines – U2OS, Saos-2, HOS, MG-63 | +/+ | Song and Li, 2018 |
| circNASP | OSC | ↑ | Augments FOXF1 expression that leads to proliferation and invasion of OS cells, positively correlates with the tumor size and metastasis | miR-1253 | Human; in vitro | Human cell lines – 143B and MG63 | +/+ | Huang et al., 2018 |
| circ_0000337 | ESCC | ↑ | Promotes cell proliferation, migration, and invasion | miR-670-5p | Human; in vitro | Human cell lines – KYSE-150, TE-1, HET-1A | +/+ | Song et al., 2019 |
| circUHRF1 | OSCC | ↑ | Modulates the transcription factor c-Myc; regulates circUHRF1/miR-526b-5p/c-Myc/TGF-β1/ESRP1 axis | miR-526b-5p | Human, Mouse; in vitro/in vivo | Human cell lines – SCC25, CAL27, SCC15, TSCCA | +/+ | Zhao W. et al., 2020 |
| circ_0082182 | CRC | ↑ | Correlated with lymph node metastasis | – | Human; in vitro | Human cell lines – HCT116, SW480, SW620, NCM460 | +/– | Ye D. et al., 2019 |
| circ_0000370 | CRC | ↑ | Correlated with lymph node metastasis | – | Human; in vitro | Human cell lines – HCT116, SW480, SW620, NCM460 | +/– | Ye D. et al., 2019 |
| circ_0035445 | CRC | ↓ | Correlated with TNM stage | – | Human; in vitro | Human cell lines – HCT116, SW480, SW620 and normal cell line-NCM460 | +/– | Ye D. et al., 2019 |
| circ5615 | CRC | ↑ | Promotes CRC progression through miR-149-5p/TNKS axis | miR-149-5p | Human, Mouse; in vitro/in vivo | Human cell lines – HCT 116, LoVo, HT-29, and SW480, NCM460 and HEK-293T | +/+ | Ma et al., 2020 |
| circ_0060745 | CRC | ↑ | Regulates miR-4736/SCE1L | miR-4736 | Human; in vitro | Human cell lines – human colon epithelial cell line (NCM460) and human CRC cell lines (HT29, LoVo, PKO, and SW480) | +/– | Wang and Wang, 2020 |
| circ_0026344 | CRC | ↓ | Correlated with metastasis | miR-21,miR-31 | Human, Mouse; in vitro/in vivo | Human cell lines – HCT116, SW480, HT29, SW620, NCM460, FHC, HEK293T | +/– | Yuan et al., 2018 |
| circ_0000567 | CRC | ↓ | Correlated with lymph metastasis, distal metastasis and TNM stage | – | Human; in vitro | Human cell lines – FHC, SW480, RKO, CACO2, SW620, HCT116 | +/– | Wang J. et al., 2018 |
| circ_0003906 | CRC | ↓ | Correlated with poor differentiation and lymphatic metastasis | – | Human; in vitro | Human cell lines: NCM460, SW480, SW620, HCT8, HCT116, HT29, LoVo | +/– | Zhuo et al., 2017 |
AML, Acute Myeloid Leukemia; CML, Chronic Myeloid Leukemia; CLL, Chronic Lymphocytic Leukemia; MM, Multiple Myeloma; BCL, B cell Lymphoma; CRC, Colorectal Cancer; BC, Breast Cancer; HCC, Hepatocellular Carcinoma; GBM, Glioblastoma; LC, Lung Cancer; NSCLC, Non-Small Cell Lung carcinoma; LAC, Lung Adenocarcinoma; GC, Gastric Cancer; BCa, Bladder Cancer; CC, Cervical Cancer; OSC, Osteosarcoma; ESCC, Esophageal Squamous Cell Cancer; OSCC, Oral Squamous Cell Carcinoma; LSCC, Laryngeal Squamous Cell Cancer; HSCC, Hypopharyngeal Squamous Cell Carcinoma.